β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphismsWan‐Ying Xie, Jie Liu, Yongjun Tang et al.|Oncology Reports|2018Cited by 28